Press release
June 4, 2026
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
Regeneron Pharmaceuticals, Inc. (REGN)
Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and